This broadcast 'SGLT2 Inhibitors and HFpEF: A Promise Fulfilled?' looks at the latest results from clinical trials studying pharmacotherapies in people with HFpEF, and current and emerging approaches in HFpEF diagnosis.
Dr Shelley Zieroth (St Boniface Hospital, CA) moderates proceedings, and is joined by an outstanding faculty, Prof Carolyn Lam (National Heart Centre, SG), Prof John McMurray (University of Glasgow, UK) Dr Scott Solomon (Brigham and Women's Hospital, US), and Dr Subodh Verma (St. Michael's Hospital, Toronto, CA), for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
Learning Objectives
- To outline current and emerging approaches in HFpEF diagnosis
- To describe the latest results from clinical trials studying pharmacotherapies in people with HFpEF
- To explain how to practically personalise HFpEF management with established and novel drugs
Target Audience
- Primary Care Physicians
- Endocrinologists
- Nephrologists
- Cardiologists
- Nurses
- Pharmacists
- Dietitians
- Diabetes Educators
More from this programme
Part 1
Welcome and Opening Remarks
| 1 session | |
| Welcome and Opening Remarks | Watch now |
Part 2
HFpEF: Unraveling the Mysteries of a Recalcitrant Medical Problem
Part 3
SGLT2i in the Treatment of HFpEF: Have They Delivered in Clinical Trials?
Part 4
From DAPA-HF to DELIVER: Does Ejection Fraction Really Matter?
Part 5
From Paper to Practice - Practical Tips for Physicians
Part 6
Q&A and Panel Discussion
| 1 session | |
| Q&A and Panel Discussion | Watch now |
Faculty Biographies
Carolyn Lam
Professor and Senior Consultant Cardiologist
Prof Carolyn Lam is a Senior Consultant Cardiologist and Director of Women’s Heart Health at the National Heart Centre Singapore, where she pioneered the country’s first Women’s Heart Clinic. Internationally recognised for her expertise in heart failure with preserved ejection fraction (HFpEF), Prof Lam has played a key role in landmark clinical trials including PARAGON-HF, EMPEROR-Preserved, DELIVER and FINEARTS-HF.
Her work helped establish the first FDA-approved treatment for HFpEF and the first trial to demonstrate robust clinical benefit in this patient population. A prolific researcher, Prof Lam has authored over 700 peer-reviewed publications in top journals such as New England Journal of Medicine, Lancet, JAMA, Circulation and